Dr. Michael S. Grable, MD
Urology (Urology Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
FL license ME0041242
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Injection, degarelix, 1 mg | 6,480 | 13 |
| Injection, denosumab, 1 mg | 3,180 | 12 |
| Manual urinalysis test with examination using microscope, automated | 1,032 | 697 |
| Established patient office or other outpatient visit, 30-39 minutes | 735 | 553 |
| Ultrasound measurement of bladder capacity after voiding | 451 | 359 |
| Insertion of needle into vein for collection of blood sample | 340 | 271 |
| Established patient office or other outpatient visit, 20-29 minutes | 289 | 255 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 257 | 64 |
| Diagnostic exam of bladder and urethra using an endoscope | 115 | 97 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 107 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Deland, FL | 207 |
| Finasteride Other prescribers in Deland, FL | 164 |
| Myrbetriq (mirabegron) Other prescribers in Deland, FL | 41 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in Deland, FL | 31 |
| Solifenacin Succinate Other prescribers in Deland, FL | 23 |
| Gemtesa (vibegron) Other prescribers in Deland, FL | 20 |
| Doxazosin Mesylate Other prescribers in Deland, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $38,431 in research payments for these studies, mostly to the institutions running them.
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Dendreon Pharmaceuticals LLC · Recruiting · NCT06134232 - BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.